Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Agilent Technologies (NY: A )

144.58 +0.33 (+0.23%)
Official Closing Price Updated: 7:00 PM EDT, Oct 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,251,199
Open 144.35
Bid (Size) 142.90 (1)
Ask (Size) 147.42 (1)
Prev. Close 144.25
Today's Range 144.07 - 146.66
52wk Range 96.80 - 155.35
Shares Outstanding 303,443,225
Dividend Yield 0.62%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
(A) - Analyzing Agilent Technologies's Short Interest
Via Benzinga
$1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today
Via Benzinga

Performance

YTD
+4.20%
+4.20%
1 Month
+4.53%
+4.53%
3 Month
+6.26%
+6.26%
6 Month
+5.69%
+5.69%
1 Year
+29.67%
+29.67%

More News

Read More
YLCHAT Triumphs on Nasdaq: A Digital Revolution in Financial Integration
Via GlobePRwire
Analyst Ratings For Agilent Technologies
Via Benzinga
AGILENT TECHNOLOGIES INC (NYSE:A) Exhibits Quality Stock Traits. Here's Why.
Via Chartmill
Agilent to Host Analyst and Investor Day on Dec. 17, 2024
From Agilent Technologies Inc.
Via Business Wire
Here's How Much $100 Invested In Agilent Technologies 20 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much $100 Invested In Agilent Technologies 20 Years Ago Would Be Worth Today
Via Benzinga
Peering Into Agilent Technologies's Recent Short Interest
Via Benzinga
$100 Invested In Agilent Technologies 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Agilent Completes Acquisition of BIOVECTRA
From Agilent Technologies Inc.
Via Business Wire
Agilent Announces Cash Dividend of 23.6 Cents per Share
From Agilent Technologies Inc.
Via Business Wire
Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine
From Agilent Technologies Inc.
Via Business Wire
Agilent Technologies Thrives From the Forever Chemicals Crackdown
Via MarketBeat
Critical Insights From Agilent Technologies Analyst Ratings: What You Need To Know
Via Benzinga
US Stocks Fall As Dollar, Treasury Yields Rise Ahead Of Fed's Jackson Hole; Oil Rebounds: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
These Analysts Boost Their Forecasts On Agilent After Strong Earnings
Via Benzinga
Agilent Navigates Market Challenges: Q3 Exceeds Expectations As Strategic Investments Pay Off
Via Benzinga
US Stocks Poised For Tepid Start Ahead Of Private Sector Activity Data And Jackson Hole Symposium: Analyst Says Market Is Focused On Nvidia Earnings And 'Waiting Is The Hardest Part'
Via Benzinga
Topics Economy
Exposures Interest Rates
A Stock Earnings: Agilent Technologies Beats EPS, Beats Revenue for Q3 2024
Via InvestorPlace
Here's How Much You Would Have Made Owning Agilent Technologies Stock In The Last 20 Years
Via Benzinga
Agilent Reports Third-Quarter Fiscal Year 2024 Financial Results
From Agilent Technologies Inc.
Via Business Wire
Nasdaq, S&P 500 Futures Edge Up As Traders Look Ahead To FOMC Minutes: Strategist Flags 3 Trends That Could Help Stocks Withstand Volatility
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Agilent Announces Innovative J&W 5Q GC/MS Columns for Superior Gas Chromatograph Performance
From Agilent Technologies Inc.
Via Business Wire
Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy
From Agilent Technologies Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.